MASTL and neoplasm: In 42.9% of gastric cancer patients, MASTL was significantly associated with cancer metastasis, tumor relapse, and poor overall survival, suggesting the potential of MASTL expression as a valuable prognostic marker and a potential therapeutic target for patients with gastric cancer.26